PharmExec Direct:
Having trouble viewing this e-mail? Click here.
You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile
PharmExec Direct | From the editors of Pharmaceutical Executive Visit the PharmExec website
Send Us Some Feedback
 

June 3 , 2010 | ISSUE NUMBER 151 VOL 8

Corporate Responsibility
Johnson & Johnson Slammed Over Manufacturing Practices, Phantom Recall
The Tylenol-making unit of J&J bore the brunt of the House Oversight Committee’s wrath when evidence emerged of a “phantom recall” and ongoing manufacturing malpractice.

Europe
Europe’s Fiscal Crisis: Can Big Pharma Emerge Unscathed?
GSK CEO Andrew Witty calls the crisis containable, but the industry’s vulnerable position in the health care delivery chain suggests it would be prudent to prepare for the unexpected–here are three scenarios that could paint P&R red.

Advertisement:
Does anybody in Life Sciences do Call & Territory Planning?
It’s been a problem for years, so you have to see this! Using update’s virtually automatic CRM tool means being analytical and efficient while rewarding for the reps. Speed, efficiency, convenience, and intelligence, for optimal business results and a better ROI. Take a look at business cases, the functionality and advantages that make you more competitive than ever! Join the free webinar – Register NOW!

Legal
Government Crackdown on the C-Suite
A new Obama Adminstration strategy intends to put fresh momentum behind stopping illegal pricing and promotion practices by big pharma. And its going to start at the top – by targeting senior executives.

// Ikaria named Douglas Greene EVP of R&D. // Xanodyne has upped COO Natasha Giordano to president and CEO, and elected her to its board. // IntegenX appointed Debi Frost VP of operations. // Richard Weiner joined Bionovo’s scientific advisory board. // Harlan Laboratories named Hilton Klein global VP, science and new product introduction and appointed Steve Jennings global VP of marketing and sales. //

Advertisement:
The Health Care Reform Opportunity: Implications and Recommendations for Life Sciences
Is health care reform a tough pill to swallow for your business? Although reform is changing the landscape, it is rife with opportunity. A report from Capgemini Consulting examines the challenges and implications resulting from health care reform and offers recommendations on how capitalize on the shifts within the industry. Download here


June 13–17, 2010 Drug Industry Association’s Annual Meeting
Washington DC

Jun 22–23 Disease Education and Bio/Pharmaceutical Product Promotion Using Social Media Tools
Alexandria, VA

Jun 28–29 Clinical R&D Compliance Forum
Philadelphia, PA

Advertisement:
Safety Document Exchange in the Global Clinical Research Environment
Serious Adverse Event (SAE) reporting can have severe repercussions both for patient safety and company reputation. By choosing a portal solution from a SaaS provider with state-of-the-art online security features, a sponsor or CRO can maintain real-time distribution and access reports for all documents shared, helping maintain compliance and data privacy. View Whitepaper

Jul 26–27 Bio/Pharmaceutical Summit: Optimize Market Research and to Drive Accurate Product Forecasts
Philadelphia, PA

Jul 29–30 5th Annual Congress on Clinical Supply Chain Management
Princeton, NJ

Sep 9–10 Clinical Trials in Latin America
Lima, Peru

Sep 29–30 6th Annual Bio/Pharmaceutical and Medical Device Product Recalls Summit
Washington, DC

Oct 5–6 International Diabetes Summit
Dubai, UAE



 
FindPharma  
Search  

Survey
If you plan to enter emerging markets over the next 3 years, what will be your primary entry strategy?
Click To Vote
Quick Links

Seeking an Objective Test for Attention Deficit Disorder

Astra Faces US Setback for Nexium Line Extension

Doctors’ Role in Drug Studies Criticized

Glaxo Settles More Avandia Lawsuits in US


Follow Pharm Exec on Twitter
User Management
| Subscribe | Update My Profile | Send Feedback | Advertise With Us | Visit PharmExec.com |

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.

Visit Pharmaceutical Executive